Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," is also covered by a corresponding patent issued by the Japan Patent Office
Silo Pharma got approval to protect a new PTSD medicine they invented. This patent gives them time to develop and sell the drug without others copying it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.